New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 14, 2014
07:55 EDTKYTHKythera price target raised to $55 from $50 at Leerink
Leeirnk raised its price target for Kythera shares to $55 after its survey indicated "significant demand" for the company's ATX-101, which aims to reduce submental fat. The firm keeps an Outperform rating on the stock.
News For KYTH From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
April 10, 2015
11:47 EDTKYTHKYTHERA rallies after BofA/Merrill reinstates with Buy, $66 target
BofA/Merrill this morning reinstated coverage of KYTHERA Biopharmaceuticals with a Buy rating and $66 price target. The firm believes the company's ATX-101 has "significant" sales potential for the treatment of double chin. If approved, ATX-101 will be the first drug indicated for double chin, BofA/Merrill noted, and the first minimally invasive option for patients to reduce chin size. Shares of KYTHERA are up $1.87 to $48.87 in midday trading.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use